The bio-tech giant
Johnson & Johnson (NYSE:JNJ) is a vocal point in a series of investment management moves. Beese Fulmer Investment Management Inc., NorthCrest Asset Manangement LLC, Andrew Hill Investment Advisors Inc., and Parallel Advisors LLC have boosted their holdings, indicating sustained investors' faith in the company. J&J has also made progress in the healthcare sector, earning places on Fortune’s 2025 America’s Most Innovative Companies list and Forbes’ best employers for tech workers list. J&J's
oncology care initiative strives to improve cancer care, while its
NJBioFutures program aims to prepare the future workforce. Despite a 1.2% drop in its stock price, its collaboration with
USAID is aimed at improving local health workforces in Latin America and the Caribbean. However, J&J faces challenges, including the court's rejection of their $10 billion talc-based bankruptcy plan and a $1.64 billion fine in a HIV drug marketing case. They are also planning to sell their stroke business for over $1 billion. Nonetheless, J&J stands resilient with earnings surpassing Q1 estimates, reinforcing its position as a valuable long-term stock.
Johnson Johnson JNJ News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sat, 31 May 2025 17:34:15 GMT -
Rating 3
- Innovation 7
- Information 6
- Rumor 2
